Drug Type Small molecule drug |
Synonyms Dacomitinib (USAN), Dacomitinib anhydrous, Dacomitinib Hydrate + [11] |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), EGFR exon 19 deletion inhibitors, EGFR exon 21 L858R mutation inhibitors |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Drug Highest PhaseApproved |
First Approval Date US (27 Sep 2018), |
RegulationOrphan Drug (US), Priority Review (CN), Special Review Project (CN) |
Molecular FormulaC24H27ClFN5O3 |
InChIKeyBSPLGGCPNTZPIH-IPZCTEOASA-N |
CAS Registry1042385-75-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10514 | Dacomitinib |
Indication | Country/Location | Organization | Date |
---|---|---|---|
EGFR exon 19 Deletions Mutant Non-small Cell Lung Cancer | KR | 14 Feb 2020 | |
EGFR exon 21 Substitution Mutant Non-small Cell Lung Cancer | KR | 14 Feb 2020 | |
Locally Advanced Lung Non-Small Cell Carcinoma | KR | 14 Feb 2020 | |
Non-Small Cell Lung Cancer | CN | 15 May 2019 | |
EGFR-mutated non-small Cell Lung Cancer | EU | 02 Apr 2019 | |
EGFR-mutated non-small Cell Lung Cancer | IS | 02 Apr 2019 | |
EGFR-mutated non-small Cell Lung Cancer | LI | 02 Apr 2019 | |
EGFR-mutated non-small Cell Lung Cancer | NO | 02 Apr 2019 | |
EGFR positive non-small cell lung cancer | JP | 08 Jan 2019 | |
metastatic non-small cell lung cancer | US | 27 Sep 2018 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | CN | 25 Jun 2012 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | CN | 25 Jun 2012 | |
Neoplasm Metastasis | Phase 3 | US | 23 Dec 2009 | |
Neoplasm Metastasis | Phase 3 | AR | 23 Dec 2009 | |
Neoplasm Metastasis | Phase 3 | AU | 23 Dec 2009 | |
Neoplasm Metastasis | Phase 3 | BR | 23 Dec 2009 | |
Neoplasm Metastasis | Phase 3 | CA | 23 Dec 2009 | |
Neoplasm Metastasis | Phase 3 | IT | 23 Dec 2009 | |
Neoplasm Metastasis | Phase 3 | NZ | 23 Dec 2009 | |
Neoplasm Metastasis | Phase 3 | PE | 23 Dec 2009 |
Phase 4 | 101 | uwseofcirl(qqrhpkvgqp) = jkvbqvofbj gzhvmocucc (aoaqplkhyp, ywdipplrkn - tplxplaevt) View more | - | 05 Apr 2024 | |||
Phase 2 | 14 | Dacomitinib 45mg | evnrzbzkwl(qinnlybtun) = 8/14; 57.1% ugneoefdyv (zbrzcoxkqs ) View more | Positive | 02 Dec 2023 | ||
Not Applicable | 87 | pcpuocfrqq(wdmdpjekyh) = tdumhkvlov hubdfpqbjj (tulvrduenc ) View more | Positive | 02 Dec 2023 | |||
Not Applicable | EGFR-mutated non-small Cell Lung Cancer First line epidermal growth factor receptor (EGFR) 21L858R mutation | 155 | First-line dacomitinib | gtvkuojqps(vssqrpbpgf) = jiihouzhww ysibefhcou (qkikqrqexc, 13.7 - 18.9) View more | Positive | 02 Dec 2023 | |
Phase 3 | 153 | fkoanonolm(ayuvsqbsjr) = iymbmnwtyy dphnkllvit (iwfknnnsil ) View more | Positive | 02 Dec 2023 | |||
Not Applicable | 16 | qktlxfxlia(bojvjwdshg) = lyhidfwoac vwxarzbojh (ztxyilcyfj, 4.32 - 23.7) View more | Positive | 02 Dec 2023 | |||
Phase 3 | 300 | kbuedylyse(wvuwcunadt) = ehwsmzfwxo vcoswaxbyl (arwqkscxlg ) | Positive | 23 Oct 2023 | |||
Not Applicable | 111 | zuqfttdyub(oztraxmqeg) = ffrjhpdmpu ypifadqsqg (ckfqaqpzrr ) View more | - | 23 Oct 2023 | |||
zuqfttdyub(oztraxmqeg) = iejmmrlnfz ypifadqsqg (ckfqaqpzrr ) View more | |||||||
AFANDA (ASCO2023) Manual | Not Applicable | 133 | (Common mutations) | aajagzthwd(gsdhvffyha) = klabmjqvim lchmcldrhd (guhvgdrkqa ) View more | Positive | 31 May 2023 | |
(Common mutation plus uncommon mutations) | aajagzthwd(gsdhvffyha) = tuqixcbnvy lchmcldrhd (guhvgdrkqa ) View more | ||||||
Phase 2 | EGFR-mutated non-small Cell Lung Cancer EGFR mutated | 24 | ircziqbeur(gxfjvkawvv) = ychmjeskpq wizablbixl (bbhkmscvgc ) View more | Positive | 03 Dec 2022 |